(Q37750050)

22 August 2017

1 reference

title

C-MET as a new therapeutic target for the development of novel anticancer drugs (English)

1 reference

22 August 2017

I Cañadas

1

1 reference

22 August 2017

F Rojo

2

1 reference

22 August 2017

M Arumí-Uría

3

1 reference

22 August 2017

A Rovira

4

1 reference

22 August 2017

J Albanell

5

1 reference

22 August 2017

E Arriola

6

1 reference

22 August 2017

publication date

1 April 2010

1 reference

Clinical and Translational Oncology

22 August 2017

published in

1 reference

22 August 2017

volume

12

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

253-260

1 reference

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12094-010-0501-0

Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-010-0501-0

Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-010-0501-0

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-010-0501-0

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase

21 January 2018

1 reference

12 December 2020

The Met tyrosine kinase receptor in development and cancer

1 reference

12 December 2020

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor

1 reference

12 December 2020

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

1 reference

12 December 2020

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

1 reference

12 December 2020

Coupling Met to specific pathways results in distinct developmental outcomes

1 reference

12 December 2020

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.

1 reference

12 December 2020

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

1 reference

12 December 2020

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair

1 reference

12 December 2020

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

1 reference

12 December 2020

Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx

1 reference

12 December 2020

Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis

1 reference

12 December 2020

Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas

1 reference

12 December 2020

Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas

1 reference

12 December 2020

Molecular cloning of a new transforming gene from a chemically transformed human cell line.

1 reference

12 December 2020

Drug development of MET inhibitors: targeting oncogene addiction and expedience

1 reference

12 December 2020

Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers

1 reference

12 December 2020

NK4 gene therapy targeting HGF-Met and angiogenesis.

1 reference

12 December 2020

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

1 reference

12 December 2020

A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts

1 reference

12 December 2020

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

1 reference

12 December 2020

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion

1 reference

12 December 2020

Molecular cancer therapy: can our expectation be MET?

1 reference

12 December 2020

Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype

1 reference

12 December 2020

c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.

1 reference

12 December 2020

Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement

1 reference

12 December 2020

Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers

1 reference

12 December 2020

c-Met is a potentially new therapeutic target for treatment of human melanoma

1 reference

12 December 2020

Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development

1 reference

12 December 2020

Met, metastasis, motility and more

1 reference

12 December 2020

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

1 reference

12 December 2020

c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays

1 reference

12 December 2020

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

1 reference

12 December 2020

Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF

1 reference

12 December 2020

NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics

1 reference

12 December 2020

Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding

1 reference

12 December 2020

A novel germ line juxtamembrane Met mutation in human gastric cancer

1 reference

12 December 2020

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

1 reference

12 December 2020

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

1 reference

12 December 2020

MET as a target for treatment of chest tumors

1 reference

12 December 2020

XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

1 reference

12 December 2020

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

1 reference

12 December 2020

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy

1 reference

12 December 2020

Met and hepatocyte growth factor/scatter factor expression in human gliomas

1 reference

12 December 2020

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation

1 reference

12 December 2020

Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors

1 reference

12 December 2020

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

1 reference

12 December 2020

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

1 reference

12 December 2020

Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript

1 reference

12 December 2020

Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors

1 reference

12 December 2020

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

12 December 2020

Invasive growth: a MET-driven genetic programme for cancer and stem cells

1 reference

12 December 2020

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

1 reference

12 December 2020

Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures

1 reference

12 December 2020

Clinical significance of c-met oncogene alterations in human colorectal cancer

1 reference

12 December 2020

Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene

1 reference

12 December 2020

Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma

1 reference

12 December 2020

Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.

1 reference

12 December 2020

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

1 reference

12 December 2020

The MET receptor tyrosine kinase in invasion and metastasis

1 reference

12 December 2020

HGF/SF-met signaling in the control of branching morphogenesis and invasion

1 reference

12 December 2020

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 reference

12 December 2020

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B

1 reference

12 December 2020

Overexpression of the Met/HGF receptor in ovarian cancer.

1 reference

12 December 2020

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

1 reference

12 December 2020

Gene amplification in gastric and esophageal adenocarcinomas

1 reference

12 December 2020

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

1 reference

12 December 2020

Cancer therapy: can the challenge be MET?

1 reference

12 December 2020

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions

1 reference

12 December 2020

Overexpression of the met/HGF receptor in renal cell carcinomas

1 reference

12 December 2020

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

1 reference

12 December 2020

Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele

1 reference

12 December 2020

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo

1 reference

12 December 2020

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

1 reference

12 December 2020

The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions

1 reference

12 December 2020

Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.

1 reference

12 December 2020

Activating mutations for the met tyrosine kinase receptor in human cancer

1 reference

12 December 2020

Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation

1 reference

12 December 2020

Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.

1 reference

12 December 2020

Interactions between scatter factors and their receptors: hints for therapeutic applications

1 reference

12 December 2020

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

1 reference

12 December 2020

The shadow of death on the MET tyrosine kinase receptor

1 reference

12 December 2020

Somatic mutations lead to an oncogenic deletion of met in lung cancer

1 reference

12 December 2020

The Sema domain of Met is necessary for receptor dimerization and activation

1 reference

12 December 2020

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

1 reference

12 December 2020

K252a inhibits the oncogenic properties of Met, the HGF receptor

1 reference

12 December 2020

Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses.

1 reference

12 December 2020

The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit

1 reference

12 December 2020

Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization

1 reference

12 December 2020

Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?

1 reference

12 December 2020

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

1 reference

12 December 2020

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

1 reference

12 December 2020

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

1 reference

12 December 2020

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

1 reference

12 December 2020

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

1 reference

12 December 2020

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

1 reference

12 December 2020

10.1007/S12094-010-0501-0

Identifiers

DOI

1 reference

22 August 2017

1 reference